During the evaluation of prostate cancer, men who have undergone transrectal ultrasound-guided biopsy with negative results present a dilemma as to what further follow-up is required. Multiple variables have been proposed throughout the literature to improve cancer detection rates not only in initial biopsy results, but also on repeat evaluation. These variables include prostate-specific antigen (PSA) velocity, PSA density, free-percent PSA, and histological findings, each of which may singly or collectively dictate the need for further biopsy. After performing a Medline literature search using specific Medical Subject Headings (prostate biopsy, repeat prostate biopsy, PSA velocity, PSA density, free-percent PSA, prostate inflammation), we critically evaluated pertinent articles. Using this accumulated data and information, we composed an algorithm to assist in the decision process for repeat biopsy.
Introduction
In 2001, 198 100 men were diagnosed with prostate cancer (CaP) in the United States and 31 500 succumbed to the disease. 1 Since the institution of serum prostatespecific antigen (PSA) in the screening process of men, much effort has been put forth to optimize discovery of clinically significant CaP. These efforts have resulted in the American Cancer Society advocating CaP screening for men in the United States starting at age 50, excepting those in high-risk groups who should start at age 45, including African-Americans and men with a positive family history. A 50-y-old man with a 25 y life expectancy has a 42% risk of having microscopic CaP, a 9.5% risk of clinically evident CaP, and a 3% risk of dying from CaP. 2 Once suspicion arises for the presence of CaP, it is necessary to obtain a tissue diagnosis. Dilemmas arise for those who have undergone biopsy for this suspicion, but have no evidence of cancer. This review will discuss the means of optimizing biopsy yields using available tests and proven biopsy techniques as well as follow-up strategies for those with previously negative biopsies.
Men who warrant evaluation for CaP by digital rectal exam (DRE) and PSA fit into two main groups: (1) those with a greater than 10 y life expectancy that would benefit from treatment and (2) those with symptoms that would necessitate palliative treatment. Indications for initial biopsy have been thoroughly reviewed in the literature, most recently by Matlaga et al. 3 The most universally applied indications include irregular DRE or PSA 44.0. In all, 22% of new CaP cases are discovered in men with normal PSA and irregular DRE. 4 This has been further stratified with PSA values 0-1, 1.1-2.5, and 2.6-4.0 resulting in positive biopsy respectively in 5, 14, and 30% of patients. Several other PSA variations have been evaluated to assist in the decision to biopsy, as we have previously described. 5 These include age-related ranges that respectively are 0-2.5, 0-3.5, 0-4.5, and 0-6.5 for men aged 40-49, 50-59, 60-69, and 70-79 y. Further variables to assist in the decision include free-percent PSA (o25%) and PSA velocity (40.75 ng/ml/y). These adjunct PSA variables are not standard screening indications for initial biopsy.
Once it is determined that an appropriate patient is at risk for possibly having CaP, a transrectal ultrasound (TRUS)-guided biopsy is performed. Prior to 1989, biopsies were most commonly lesion-directed. However, Stamey's group at Stanford University illustrated that in diagnosing CaP, systematic biopsies in a sextant format in addition to lesion-directed biopsies were superior to lesion-directed alone. 6 Several groups have since demonstrated that complementing the sextant format with further biopsies will optimize cancer detection rates without increasing morbidity. [7] [8] [9] [10] Regardless of the increased number of biopsies that are obtained, detection rates are still typically only 30-44%. 7, 9 In the remaining patients the question is whether the elevated PSA is due to other causes vs cancer that went undetected. It is in these patients that a quandary exists as to how and when to perform further evaluations.
Biopsy technique
The motive for sextant biopsies was based on the fact that the majority of tumors are located in the peripheral zone (PZ) of the prostate and that the majority of patients with cancer do not have a palpable prostate nodule. Recently, the relationship of prostate volume to CaP detection rate has been scrutinized. While initial evaluation of this issue revealed an increased false-negative rate in biopsies for those with increased volumes, further studies have yielded mixed results. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] These studies have also addressed the need for extended biopsy schemas in larger volume prostates. Ung et al 18 demonstrated no statistical difference in CaP detection rates in patients undergoing increased numbers of biopsies beyond nine cores. Furthermore, their yields did not increase with extended schemas in larger volume prostates. Explanations included increased PSA due to BPH, as well as biopsies being performed more commonly for elevated PSA rather than irregular DRE with/without elevated PSA. Contrasting the findings of Ung et al are recent studies by two other groups. Remzi et al 16 showed that there were increased numbers of cancers discovered on repeat biopsy for those with prostate volume 20-80 cm 3 and for those whose TZ volume was 9-40 cm 3 . Beyond these size limits, they discourage repeat biopsy excepting cases with high likelihood of containing cancer (e.g. high-grade prostatic intraepithelial neoplasia (PIN), rising PSA). It is further discussed that performing two sets of sextant biopsies is debatable, and that it may be preferential to instead increase the number of biopsy cores in those with increased volumes. Basillote et al 17 also demonstrated increased false-negative rates in patients with increased prostate volumes. They stratified patients into two groups using different cutoff points: o37.5 or Z37.5 cm 3 and o50 or Z50 cm 3 . Respective findings of CaP on repeat biopsy in these two groups was 6.2 and 12.5% for the 37.5 cm 3 group and 6.5 and 13.7% for the 50 cm 3 group. They offer as explanation both the obvious reason of undersampling of a proportionally smaller amount of tissue and the finding of Chen et al 22 that larger glands have been noted with more small-volume (r0.5 cm 3 ) tumors. The decision whether to extend the number of cores has been thoroughly addressed throughout the literature as discussed above. For those who continue to perform the traditional sextant schema, it has been suggested that in prostates with volumes exceeding 30 cm 3 , extended biopsies are warranted and may preclude repeat biopsy by optimizing detection rates. 23 
PSA
As mentioned, men with PSA above 4 or values in the age-specific ranges that are concerning for cancer should be considered for prostate biopsy. For that majority who return with no cancer, PSA parameters can facilitate the decision to repeat biopsies. These include PSA velocity (PSAV), PSA density (PSAD), and percent-free PSA.
PSA velocity
The rate at which PSA changes can reflect the probability of cancer existing. The velocity is determined by taking the difference between two PSA values and dividing by the time interval in years. Carter et al 24, 25 initially proposed that increased velocities greater than 0.75 ng/ ml/y were reflective of existing prostate cancer. Borboroglu et al 26 evaluated 57 men with previously negative biopsies. Using a velocity of 0.75 or 1.0 ng/ml/y as a cutoff, biopsies would have only been required in 36 and 25 men, respectively, to detect cancer in 16 of the 17 men who were found with cancer on repeat procedure. This would have avoided biopsies in 21 and 32 men again using the respective cutoffs of 0.75 and 1.0 ng/ml/y. Of the PSA parameters analyzed, they concluded that PSAV was the only statistically significant risk factor for positive biopsy. However, Keetch et al 27 studied 327 men with previously negative prostatic biopsies. They determined that including only those with PSAV (slope) greater than 0.75 ng/ml/y would reduce the number who required repeat biopsy, but that velocity alone 
PSA density
The primary cause of elevated PSA in men with values less than 10 ng/ml is enlargement of the prostate. To normalize this occurrence, PSAD has been evaluated and is calculated by dividing the PSA value by the prostatic volume. It has been shown that increased PSAD is reflective of the existence of cancer. Keetch's group evaluated density to assist in determining the need for a repeat biopsy. Using a value of 0.15 ng/ml/cm 3 , they reported missing 35% of the cancers. However, in conjunction with a PSAV40.75 ng/ml/y, they had a detection rate of 46% on repeat biopsy, vs only 13% when both values were below the suggested cutoff. Djavan et al 28 evaluated PSAD, but showed increased utility when it was related to TZ volume only-termed PSA-TZ. Using a value of 0.13 and 0.26 ng/ml/cm 3 for PSAD and PSA-TZ, respectively, they report sensitivities of 74 and 78% and specificities of 44 and 52%, respectively.
They reiterate Zlotta's findings that the PSA-TZ is reliable in its reproducibility, but concede the difficulty in measuring it, particularly in small-or large-volume prostate glands. 29 Although density has not been uniformly supported as a single indicator for repeat biopsy, it does provide information that can be used in conjunction with other values.
Free/total PSA (free-percent)
The majority of PSA is attached to one of two large molecules in the serum-alpha 1 -antichymotrypsin or alpha 2 -macroglobulin. The remainder is classified 'free' and is decreased in proportion to bound PSA in those with cancer or infection. When infection is absent on initial biopsy, free PSA has good utility in predicting cancer presence, specifically in men with PSA 4-10 ng/ ml. Catalona et al 30 demonstrated the most comprehensive study, showing that using a free-percent PSA cutoff of less than 25% prevented 20% of unnecessary biopsies and still diagnosed 95% of existent cancers. As a means of determining the need for repeat biopsy, Djavan et al 15 used a cutoff of 30% and eliminated 50% of biopsies while detecting 90% of cancers. Free-percent PSA is especially useful with values in the lower range, as expressed by Morgan et al. 31 They demonstrated that free PSA less than 10% was indeed a strong predictor for prostate cancer, even after two negative biopsies with sensitivity and specificity rates of 91 and 86%, respectively. Such findings are stimulus to perform repeat biopsies on a more immediate schedule.
Histopathology
Pathologic findings on initial biopsy-including atypia and high-grade PIN-may also suggest an increased likelihood that cancer is present. Most significant is highgrade PIN. It is considered a cancer precursor and has been shown to be existent in the presence of CaP in greater than 85% of cases, making it a strong predictor. 32 It should be mentioned that low-grade PIN is not associated with existing cancer, and has been discouraged from being mentioned in pathologic analysis.
Results for repeat biopsies are varied when either high-grade PIN or atypia is present. Several studies show cancer in over 40% of such patients as tabulated by Park et al 33 (Table 1) . They reported a 51% cancer detection rate in those with high-grade PIN or atypia. PIN does not always exist immediately adjacent to cancer cells, and may be multifocal throughout the prostate. Park's group demonstrated that 88% of such cancers were detected in either the sextant region containing the atypia or immediately adjacent sextant sites, and that 12% were in regions neither in nor adjacent to those containing high-grade PIN.
Patients who have high-grade PIN should undergo repeat biopsy without further evaluation. If repeat biopsy is negative for cancer, it is recommended that these patients undergo PSA check and TRUS biopsy every 6 months for 2 y and annually thereafter. 34 PSA levels are known to increase in the face of prostatic infection. Although the precise etiology is not clear, it is suspected that this results by either leakage of PSA from epithelial cells into the serum or through paracrine stimulation of epithelial cells by inflammatorymediated substances resulting in increased PSA. 35, 36 Findings of chronic or acute inflammation on TRUS biopsy have been evaluated to assess the frequency of PSA elevation in the absence of CaP. Nadler et al 37 noted that prostate inflammation and volume were the most important factors resulting in PSA elevations in those without CaP. This was reiterated most recently by Okada et al, 35 who found that histologically acute inflammation was the only independent determinant of serum PSA in those with prostates smaller than 25 g. It should be mentioned that while inflammation may inflate total PSA, it does not appear to clearly impact the free-percent PSA. 38 Although it has not been clinically validated, interval antibiotic administration to correct PSA elevation secondary to histologic inflammation may help PSA reach its true baseline. At the authors' institution, patients with elevated PSA levels who have biopsies showing only inflammation are prescribed a 4-week course of antibiotics (eg fluoroquinolones) followed by repeat analysis of the serum PSA. Significant decreases to levels still above 4 ng/ml result in consideration for rebiopsy, while those in whom PSA descends below 4 ng/ml are returned to the routine annual screening protocol.
While it is shown that men with PSA levels 2. Figure 1 Algorithm to assist in the management of previously negative TRUS biopsy.
Repeat prostate biopsy JE Busby and CP Evans lowering the PSA cutoff to recommend biopsy in younger men would improve the utility of PSA as a means of optimizing cancer detection.
Timing of biopsy (immediate vs delayed)
For those patients in whom a repeat biopsy may be warranted, determining the timing for the procedure is the next step in the algorithm. Patients with the greatest risk for existing cancer should optimally undergo repeat biopsy without delay. The exact interval is not clearly defined; at the author's institution repeat biopsy is typically performed within 2-4 weeks. As previously discussed, such patients include those with concerning histopathology as with atypia or high-grade PIN. Others fitting this high-risk category include patients without inflammation on initial biopsy whose PSA is 410 or with both a PSA 4-10 and free-percent o10%. 35 Of these subpopulations, 450 and 56% have respectively been shown to have cancer. 30 The remaining patients with previously negative biopsies can be followed with interval serum PSA and free-percent PSA every 3-6 months to assess PSAV. Should these values not prompt repeat biopsy after 1 y, we recommend annual PSA and free-percent with DRE to continue thereafter. Table 2 lists criteria for immediate vs delayed repeat biopsies.
Conclusion
The dilemma of previously negative biopsies in men suspicious for prostate cancer has been addressed by multiple studies. The yield of the second biopsy set is multifactorial and depends on the likelihood that cancer is present, the technique of the initial and repeat biopsies, and the means of patient selection. Various values have been presented and range from 10 to 30%. There has been no consensus on which variables are most reliable in predicting the presence of prostate cancer on repeat biopsies.
Djavan et al 28 recently performed a review of these variables in determining on whom to perform repeat biopsies. While their study was comprehensive and very good, some issues should be addressed. Several groups have shown that the most effective biopsy schema includes the sextant format as well as 2-4 cores of the lateral horns of the PZ. As mentioned above, TZ biopsies, which were performed in their initial and repeat biopsies, provide low yield. This, in conjunction with the performance of only sextant PZ biopsies, may be responsible for their comparatively low yield on initial and repeat biopsies (initial ¼ 22%; second ¼ 10%; third ¼ 5%; fourth ¼ 4%). When using free-percent PSA, Catalona et al showed that using a value of 25% or less eliminates 20% of repeat biopsies while still detecting 95% of cancers. Djavan's et al's use of a free-percent PSA of 30% may include additional unnecessary biopsies. Finally, the use of PSA-TZ may not be reproducible or practical for many urologists given the variability in experience and resources. Should one be an experienced sonographer with high-resolution probes, PSA-TZ combined with other variables should aid in the decision to repeat biopsy.
Others have scrutinized the aforementioned variables with the goal of minimizing morbidity while maximizing clinically significant cancer detection. It can be deduced that such optimization may reduce initial or repeat biopsies in excess of 10%. Using the prevalently available data in conjunction with these variables, we have constructed an algorithm to assist in the decision to repeat TRUS biopsies in warranted patients (Figure 1 ).
